Video

Dr. Al-Sawaf on the Benefit of Fixed-Duration Obinutuzumab/Venetoclax in CLL

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, physician, the University Hospital of Cologne, discusses the benefit of fixed-duration treatment with obinutuzumab (Gazyva) plus venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

In the phase 3 CLL14 trial (NCT02242942), investigators evaluated the efficacy and safety of fixed-duration obinutuzumab plus venetoclax vs obinutuzumab plus chlorambucil in patients with previously untreated CLL with preexisting conditions.

Five-year follow-up data showed that fixed-duration obinutuzumab plus venetoclax demonstrated a clear benefit, particularly regarding toxicity, Al-Sawaf says. Since adverse effects were observed only when patients were on treatment, the lack of prolonged toxicity gives fixed-duration treatment another advantage, Al-Sawaf concludes.

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS